

CURRICULUM VITAE

Gerri Tripp

OFFICE LOCATION:

Leavitt Management (DBA)
Ameriderm Research
Clinical Trials Manager
725 West Granada Blvd., Suite 44
Ormond Beach, FL 32174
Office #: (386) 898-0547
Cell # (904) 248-8114
gtripp@ameridermresearch.com

Leavitt Management Group Inc. (DBA)
Ameriderm Research
903 Central Avenue
Kissimmee, FL 34741
Office: (407) 705-5100 Fax: (407) 215-0294

Leavitt Management Group Inc. (DBA)
Ameriderm Research
4100 Southpoint Dr. East, Suite 1
Jacksonville, FL 32216
Office: (904) 483- 2228 Fax: (904) 854-2555

MEDICAL LICENSE:

FL LPN License

CERTIFICATION:

Basic Life Support

DEGREE:

LPN

EDUCATION:

1985-1986

Swainsboro Technical School
346 Kite Road
Swainsboro, GA
Ph# (912) 289-2200
Fax# (912) 289-2263

WORK EXPERIENCE:

- 03/2007 – 02/2008 University of Florida Health Science Center/Jacksonville
Program Manager Neurology Research
580 West 8th Street, Tower 1, 8th Floor
Jacksonville, FL 32209
Office #: 904-244-9814
- 05/2005 – 3/2007 Inpatient Clinical Research Coordinator
Jacksonville Heart Center
836 Prudential Drive, Suite 1700
Jacksonville, FL 32207
Ph# 904-398-0125 X- 1450
- 05/2002 – 5/2005 Inpatient Clinical Research Coordinator
Diagnostic Cardiology Associates
1800 Barrs Street
Jacksonville, FL 32204
Ph # 904-388-1820
- 2000 – 2002 Inpatient Clinical Research Coordinator
Jacksonville Center for Clinical Research
4004 University Blvd. South
Jacksonville, FL 32216
Ph#: 730-0101
Fax#: 730- 9199
- 09/1996 – 02/2000 Inpatient Clinical Research Coordinator
University of Florida Health Science Center/Jacksonville
655 West 8th Street; Jacksonville, FL
Ph# - 244- 9650
Fax# - 244- 9668
- 07/1994 – 09/1996 Office Nurse Manager
Nephrology Office
Riverside Clinic
Jacksonville, FL
- 09/1993 – 07/1994 Nurses PRN
Jacksonville Area Hospital Staffing Relief
- 07/1992 – 09/1993 Telemetry Staff Nurse
St. Vincent's Medical Center
1800 Barrs Street; Jacksonville FL 32204
Ph# 308-7300
Fax # - 308- 2935
- 07/1990 – 06/1992 Staff Nurse – Step Down Unit

Memorial Medical Center
4700 Waters Avenue
Savannah, GA
Ph # - (912) 350-8000
Fax # - (912) 350-3383

08/1989 – 06/1990 Hemodialysis Nurse
Vidalia Dialysis Unit; Vidalia, GA 30474

09/1985 – 05/1989 Staff Nurse
Meadows Regional Medical Center
504 Maple Drive
Vidalia, GA 30474
Ph # - (912) 537- 8921

RESEARCH EXPERIENCE:

2009 – present Efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy

2009 – present Phase III, multicenter, randomized double-blind study evaluating the safety and efficacy of a topical solution in patients with mild to moderate onychomycosis of the toenails.

2009 – present Study of the efficacy, safety and tolerability of study drug in adults with a diagnosis of atopic dermatitis with moderate to very severe pruritus

2009 – present Evaluate the bioequivalence of two tacrolimus topical ointment formulations in patients with moderate to severe atopic dermatitis

03/2009 – 11/2009 A phase II study evaluating the safety and efficacy of study drug applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas

02/2009 – 10/2009 A randomized, double blind, placebo controlled, parallel group, multicenter study to determine the efficacy and safety of two dose levels of study drug compared with placebo in subjects with type II diabetes mellitus

02/2009- 10/2009 A randomized, double blind, placebo and active controlled, parallel group multicenter study to determine the efficacy and safety of study drug administered in combination with metformin and glimepiride compared with metformin plus

	glimepiride and placebo and with meftormin plus glimpiride and pioglitazone in subjects with type II diabetes mellitus
02/2009 – 10/2009	A randomized, double blind placebo controlled, parallel group , multicenter study to determine the efficacy and safety of study drug when used in combination with pioglitazone with or without metformin in subjects with type II diabetes mellitus
04/2009 – Present	A randomized, open label, parallel group, multicenter study to determine the efficacy and long term safety of study drug compared with insulin in subjects with type II diabetes mellitus
04/2009 – present	A randomized, double blind, placebo and active controlled, parallel group, multicenter study to determine the efficacy and safety of study drug in subjects with type II diabetes mellitus.
2008 – present	A pivotal phase III, multicenter, single-arm, two cohort trial evaluating the efficacy and safety of the study drug in patients with advanced basal cell carcinoma
02/2008 – 11/2008	A Multi-Center Randomized, Double-Blind, Placebo Controlled Study of 0.10% OR 0.05% PTH (1-34) Gel In The Treatment of Mild To Moderate Plaque Psoriasis
02/2008 – 10/2008	A Multi-Center, Double-Blind, Vehicle-Controlled Study Comparing Imiquimod Cream, 5% (Apotex Inc.) To Aldara Cream, 5% (3M Pharmaceuticals, US) And Aldara Cream, 5% (3M Pharmaceuticals, Canada) In The Treatment Of Actinic Keratosis
02/2008 – 10/2008	A Double-Blind, Randomized, Parallel-Group Placebo-Controlled, Multi-Center To Evaluate the Safety and Clinical Equivalence of Generic Imiquimod Cream 5% To Aldara Cream 5% and both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis of The Face or Scalp
02/2008 – 10/2008	A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Clinical Equivalence of Generic Metronidazole Gel, 1% to Metrogel, 1% and both Active Treatments to a Vehicle Control in the Treatment of Inflammatory Rosacea Lesions.
04/2008 – present	An open label, safety, tolerability, pharmacokinetic (PK), Pharmacodynamic (PD) and preliminary efficacy study of INCB018424 when applied to patients with plaque Psoriasis involving 2 – 20% body surface area (BSA)

04/2008 – 10/2008	A Multi-Center, Open-Label, Dose-Area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days To Treatment Area(s) of Up To A Total of 100 cm squared in Patients With Actinic Keratosis On The Extensor (Dorsal Aspect) Forearm(s).
05/2007 – 01/2008	<u>SENTIS</u> - S afety and E fficacy of N euroFlo T echnology in I schemic S troke (SENTIS)
03/2007 – 01/2008	<u>IRIS</u> – Insulin Resistance after Stroke
03/2007 – 01/2008	<u>LIONS</u> – L ocal I dentification and O utreach N etwork for S troke Trial Recruitment
05/2005 – 03/2007	<u>Madit-CRT</u> – Guidant Multicenter Automatic Implantation Trial with Cardiac Resynchronization Therapy
05/2005 – 03/2007	<u>PACE CABG</u> - Guidant Pacing Effect in CABG subjects with prior MI
05/2005 – 03/2007	<u>GDT 1000 Acute Sensing Trial</u>
05/2005 – 03/2007	<u>Site Line</u> – Advanced Pacing Lead – Guidant
05/2005 – 03/2007	<u>4195</u> – Attain StarFix – Model 4195 Left Ventricular Lead
03/2005 – 5/2005	<u>SPIRIT III</u> – A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent (EECS) System in the Treatment of Subjects with de novo Native Coronary Artery Lesions
03/2005 – 03/2007	<u>PEGASUS CRT</u> – Pacing Evaluation – Atrial Support Study in cardiac Resynchronization Therapy
10/2004 - 5/2005	<u>AWARE</u> - A nalysis of a N ew A T/ A F Detection A lgorithm In P atients with Atrial Arrhythmias
07/2004 – 03/2007	<u>BLOCK HF</u> - Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block
07/2004 – 5/2005	<u>REFLEX</u> - ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance
02/2004 - 5/2005	<u>FAST</u> – Fluid Accumulation Status Trial
08/2003 – 5/2005	<u>INTRINSIC RV</u> – Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICD's

12/2002 – 07/2003	<u>Reactive ATP Download Study</u> – Using the GEM III Implantable Cardioverter Defibrillator
11/2002 – 5/2005	<u>InSync ICD</u> – Post Market Registry Cardiac Resynchronization Therapy
10/2002 – 06/2003	<u>Rhythm ICD</u> – Resynchronization for Hemodynamic Treatment for Heart Failure Management
08/2002 – 03/2007	<u>InSync Registry</u> – InSync Post market Registry Cardiac Resynchronization Therapy
09/2002 – 5/2005	<u>Empiric Trial</u> – Evaluation of EMPIRIC Programming to Improve Patient Management
05/2002 – 5/2005	<u>PAVE</u> – Left Ventricular Based Cardiac Stimulation Post AV Node Ablation Evaluation
05/2002 – 10/2002	<u>MIRACLE ICD</u> -InSync® ICD Clinical Study
05/2002 – 08/2003	<u>Rate Response Optimization</u> – St. Jude Medical
05/2002 – 12/2002	<u>ACED – AF</u> - Medtronic Arrhythmia Management Clinical and Outcomes Research
12/2001- 5/2003	<u>REPLACE 2</u> Phase IIIb, Randomized, Open-Label Study Conducted in Two Parts To Demonstrate That Angiomax As The Foundation Anticoagulant With Discretionary Use Of GP IIb/IIIa Inhibitors Provides Clinical Outcomes At Least As Good As The Current Optimal Therapy Of Low Dose, Weight Adjusted Heparin Plus GP IIb/IIIa Inhibitor, But At a Lower Economic Impact. A Randomized Evaluation in PCI Linking Angiomax To Reduce Clinical Events.
11/2001- 12/2003	<u>SYNERGY</u> A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS) ENO. GMA. 301
5/2003- 5/2005	<u>TAXUS IV</u> A Prospective, Randomized, Controlled, Double- Blind, Multicenter Study to Evaluate the Safety and Efficacy of the Study Device in the Treatment of De Novo Lesions.
6/2003- 5/2005	<u>ACTIVATE</u> A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease Using Intravascular Ultrasound (IVUS).

10/2003- 5/2005	<u>RESPECT</u> A Randomized Evaluation of Recurrent Stroke Comparing PFO closure to Established Current Standard of Care Treatment. The AMPLATZER PFO Occluder is percutaneous, transcatheter occlusion device intended for the non-surgical closure of patent foramen ovale (PFO) in patients who have had a cryptogenic stroke due to presumed paradoxical embolism within the last 90 days. IDE and HDE protocols
6/2003- 5/2005	<u>MAVERIC II</u> The Evaluation of the Medtronic Ave Self-Expanding Carotid Stent System with Distal Protection in the Treatment of Carotid Stenosis. The purpose of Maveric II is to demonstrate the safety and efficacy of the Self-Expanding Carotid Stent System with the Guardwire 3-6 Temporary Occlusion & Aspiration System for the treatment of carotid stenosis.
4/2003- 5/2005	<u>SPIDER SVG</u> Protection In a Distal Embolic Protection Randomized Trial. The purpose of SPIDER is to establish the safety and efficacy of the Spider Embolic Protection Device during the percutaneous interventional treatment of saphenous vein graft lesions.
2/2003- 5/2004	<u>CAMPER</u> Clopidogrel and Aspirin in the Management of Peripheral Endovascular Revascularization. Effect of Clopidogrel vs. Placebo, on a background of standard care including aspirin, in maintaining the patency of lower limb arteries after angioplasty.
3/2004- 5/2005	<u>Pfizer A509-1005</u> A Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529, 414 / Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared with Atorvastatin Alone, in Subjects with Angiographically Documented Coronary Heart Disease.
6/2004-5/2005	<u>LUNAR</u> A 12- Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIB Study Comparing the Efficacy and Safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in Subjects with Acute Coronary Syndromes.
12/2004- 5/2005	<u>TAXUS Arrive 2 REGISTRY</u> A Multi-Center Safety Surveillance Registry.
11/2004- present	<u>AMETHYST-</u> A Multi-center, non-inferiority, randomized, controlled trial to evaluate the safety and efficacy of the

Medtronic Ave Interceptor coronary filter system in subjects with de novo and restenotic lesions of SVG's.

11/2000 – 05/2002	<u>Immunex 016.0021 – RENAISSANCE -</u> Patients with Congestive Heart Failure –TNFR (Class II – IV)
2000 – 05/2002	<u>A-STAR</u> – Proctor and Gamble – Symptomatic Paroxysmal Atrial Fibrillation with Azimilide
2000 – 05/2002	<u>A-COMET</u> – Proctor and Gamble – Symptomatic Atrial Fibrillation with Azimilide
2000 – 03/2002	<u>EPHESUS – IE3-99-02-035</u> – Searle / Patients with heart failure following acute myocardial infarction
2002 – 05/2002	<u>ADONIS</u> – Sanofi-Synthelabo – EFC4788 – Atrial Fibrillation
2000 – 2000	<u>DE031</u> – Rheumatoid Arthritis
2000 – 2000	<u>SONORA</u> – New Onset Rheumatoid Arthritis
2000 – 2000	<u>N91-02-067</u> – Rheumatoid Arthritis
2000 – 2000	<u>N91-02-047</u> – Rheumatoid Arthritis
1997 – 2002	<u>LIFE</u> – Reduction of morbidity and mortality in hypertensive patients with LVH
1996 – 2000	<u>CESNA-II</u> – Evaluate the comparative efficacy and safety of Nisoldipine and Amlodipine with hypertensive patients with ischemic heart disease
1997 – 1999	<u>SYMPHONY</u> – Aspirin-controlled study to evaluate Sibrafiban - An oral platelet glycoprotein IIb/IIIa; Prevention of secondary vascular events in patients after acute coronary syndrome
1996 – 1997	<u>STRATUS</u> – A study to determine rotablator and transluminal angioplasty strategy
1997 – 1999	<u>BEST</u> – Beat-Blocker Evaluation of Survival Trial
1997 – 1999	<u>HOPE</u> – Heart Outcomes Prevention Evaluation
1998 – 2000	<u>PRAISE 2</u> – Prospective randomized amlodipine survival evaluation
1998	<u>CANDESARTAN PILOT TRIAL</u> – Candesartan with Heart Failure

1999 – 2000

GROWTH HORMONE – with Heart Failure

1999 – 2000

RENAISSANCE – TNFR with Heart Failure